<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515694</url>
  </required_header>
  <id_info>
    <org_study_id>BRIDION_ERASME</org_study_id>
    <nct_id>NCT03515694</nct_id>
  </id_info>
  <brief_title>Minimal Optimal Dose of Sugammadex in Elective Surgery</brief_title>
  <official_title>Minimal Optimal Dose of Sugammadex in Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Time of appearance of TOF Ratio &gt;0,9 with different doses of Sugammadex
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: monocentric, prospective, controlled, randomized, double-blind study Inclusion
      criteria: women and men&gt; 18 years old, elective surgery, BMI &lt;30, patients giving consent to
      free and informed participation in writing;

      Exclusion criteria:

        -  minor patients;

        -  Patients refusing to sign the consent;

        -  Patients included in another protocol within 3 months;

        -  Pregnant or lactating patients;

        -  Patients with a history of allergy to Sugammadex;

        -  Patients with known neuromuscular disease;

        -  Patients with renal or hepatic impairment.

      Course of the study :

        -  40 patients will be recruited at the time of the anesthesia consultation and randomized
           to double blind in 8 groups (the day before surgery)

        -  All patients will benefit from general anesthesia. Anesthetic management

           (1- 3mg / kg / IV propofol, 0.2 Î¼g / IV sufentanil, 0.6 mg / kg rocuronium and
           maintenance anesthesia with sevoflurane) will be standardized for all patients.

        -  Upon administration of rocuronium the acceleromyography transducer will be attached to
           the distal phalanx of the thumb, and repeated TOF stimulation will be applied to the
           ulnar nerve wrist at intervals of 15 seconds. Neuromuscular monitoring is continued
           until the end of the anesthesia.

        -  Once the first answer (1st twitch) appeared a dose of sugammadex will be administered
           according to the group whose patient was randomized: Test Groups Control Groups Group 1:
           Placebo + TOF 1 Group 1bis: Placebo + TOF2 Group 2: 0.5 mg / kg + TOF1 Group 2bis: 0.5
           mg / kg + TOF2 Group 3: 1mg / kg + TOF1 Group 3bis: 1mg / kg + TOF2 Group 4: 2mg / kg +
           TOF 1 Group 4bis: 2mg / kg + TOF 2

        -  Then a standard dose of 4mg / kg will be administered at the end of the procedure before
           awakening to all patients who have signs of residual curarization (TOF ratio &lt;0.9). The
           pharmacy will be responsible for preparing the different doses of sugammadex, the
           syringe will be carefully covered and packaged, will contain an equal volume so that the
           anesthetists do not know which group the patient belongs to. Data collection: In real
           time during the intervention by the anesthesiologist in charge of patient Method of
           Analysis: Analysis of intent-to-treat data
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel, Double blind Monocentric Prospective Vs placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the recovery time of the ratio 0.9.</measure>
    <time_frame>1 hour</time_frame>
    <description>Evaluate the recovery time of the ratio 0.9.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of appearance of 4 responses to the TOF</measure>
    <time_frame>1 hour</time_frame>
    <description>Time of appearance of 4 responses to the TOF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the four-to-four ratio &lt;0.7 after total recovery.</measure>
    <time_frame>1 hour</time_frame>
    <description>Evaluate the four-to-four ratio &lt;0.7 after total recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Watch time at the recovery room.</measure>
    <time_frame>4 hours</time_frame>
    <description>Watch time at the recovery room.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Time of a TOF Ratio &gt;0,9</condition>
  <arm_group>
    <arm_group_label>Dose of 0mg/kg TOF1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 0mg/kg TOF2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 0 ,5mg/kg TOF1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 0,5mg/kg TOF2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 1mg/kg TOF1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 1mg/kg TOF2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 2mg/kg TOF1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of 2mg/kg TOF2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex Injection [Bridion]</intervention_name>
    <description>Injection of 10mL of translucide solution</description>
    <arm_group_label>Dose of 0mg/kg TOF1</arm_group_label>
    <arm_group_label>Dose of 0mg/kg TOF2</arm_group_label>
    <arm_group_label>Dose of 0 ,5mg/kg TOF1</arm_group_label>
    <arm_group_label>Dose of 0,5mg/kg TOF2</arm_group_label>
    <arm_group_label>Dose of 1mg/kg TOF1</arm_group_label>
    <arm_group_label>Dose of 1mg/kg TOF2</arm_group_label>
    <arm_group_label>Dose of 2mg/kg TOF1</arm_group_label>
    <arm_group_label>Dose of 2mg/kg TOF2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        women and men&gt; 18 years of age Elective Surgery BMI &lt;30, patients who gave consent to free
        and informed participation in writing

        Exclusion Criteria:

          -  minor patients;

          -  patients refusing to sign consent;

          -  patients included in another protocol within 3 months;

          -  pregnant or nursing patients;

          -  patients with a history of allergy to Sugammadex;

          -  patients with known neuromuscular disease

          -  patients with renal or hepatic impairment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy FERNANDEZ, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier DURANTEAU, Trainee</last_name>
    <phone>+33673070541</phone>
    <email>olivier.duranteau@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier DURANTEAU, PG</last_name>
      <phone>+33673070541</phone>
      <email>olivier.duranteau@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bridion</keyword>
  <keyword>Sugammadex</keyword>
  <keyword>TOF</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

